NCT04338958View on ClinicalTrials.gov

Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation

PHASE2CompletedINTERVENTIONAL

Enrollment

193

Participants

Timeline

Start Date

April 22, 2020

Primary Completion Date

July 15, 2021

Study Completion Date

July 15, 2021

Conditions

Covid-19

Interventions

DRUG

Ruxolitinib

2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days with clinical and/or radiographic response assessment

Trial Locations (6)

23538

UKSH, Campus Lübeck, Lübeck

70174

Klinikum der Landeshauptstadt Stuttgart gKöR, Stuttgart

78052

Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH, Villingen-Schwenningen

89081

Universitätsklinikum Ulm, Ulm

07548

SRH Wald-Klinikum Gera GmbH, Gera

07747

University Hospital Jena, Jena

All Listed Sponsors

lead

University of Jena

OTHER

NCT04338958 - Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation | Biotech Hunter | Biotech Hunter